Member Profile

EXCELSIOR BIOPHARMA INC., founded in Taipei City, Taiwan in 1986, has developed the service to import and distribute of medicines to clinics, hospitals, and pharmacies for more than three decades. Engaging in providing services across R&D, production, biomedical and genetic testing, commercialization, healthcare and patient care. We continue to improve professional knowledge, healthcare guidelines and genetic technology of the teams and healthcare groups to assist patients in Taiwan and Asia to have optimal and good quality healthcare services.

The abilities of EXCELSIOR are including research and development of new drugs and integrate manufacturing, and its medical laboratory technology. We work with domestic research institutions and medical centers successively to apply the existing technology to develop new products and new indications under the industry–academia collaboration projects. Pursuing future trends for gene therapy in research for rare disease, we expect to seek collaboration with top scientists and innovation biotech companies.

EXCELSIOR adheres to the consistent management philosophy, continue to pursue excellence, care the society, provide better healthcare services for healthcare professionals and patients, and take the responsibility owed to the country and society.

Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   1988 Corporate Establishment
   1996 Excelsior applied and built up R&D center in the Incubation Center of ITRI and founded the subsidiary of Excelsior Pharmatech Labs.
   2012 The molecular biology and metabolic biochemistry lab was set up to develop the patient screening and diagnostic methods of genetic and metabolic disorders.
   2014 Excelsior Pharmatech Labs awarded Taiwan FDA PIC/S GMP certification.
   2016 Excelsior’s stock was listed in the OTC market.
   2016 OMACOR® obtained marketing authorization as NCE by Taiwan FDA.
   2016 Excelsior inaugurated TGF-β Research Center.
   2017 Excelsior awarded Taiwan FDA PIC/S GDP certifications.
   2017 Awarded the 26th Small and Medium Enterprise by Ministry of Economic Affairs
   2018 Obtained the Certificate of PIC/S GMP from Taiwan FDA
   2020 Established Asia-Pacific Rare Disease Research Center
   2021 Rated among the Top 5% in 7th Corporate Governance Rating of TPEx Listed Companies
   2021 Invested Excelsior Biological Medicine Inc. to focus on research in the field of natural substances